Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» EDIT-101
EDIT-101
Where Will Editas Medicine Be in 1 Year?
Motley Fool
Sun, 11/20/22 - 12:52 pm
Editas Medicine
EDIT-101
Leber's congenital amaurosis
Editas halts lead CRISPR program after efficacy data underwhelm
Endpoints
Thu, 11/17/22 - 12:10 pm
Editas Medicine
CRISPR
EDIT-101
clinical trials
Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101
BioSpace
Wed, 11/2/22 - 10:54 pm
Editas Medicine
EDIT-101
gene therapy
Leber's congenital amaurosis
Editas' gene-editing data has company touting prime time based on early vision improvement signals but questions remain
Fierce Biotech
Wed, 09/29/21 - 11:12 am
CRISPR
Editas Medicine
gene editing
EDIT-101
vision loss
Why Editas Medicine Stock Is Tumbling Today
Motley Fool
Mon, 01/11/21 - 06:50 pm
Editas Medicine
JPMHC 2021
EDIT-301
EDIT-101
Editas, Allergan launch first in vivo study of CRISPR-based medicine
BioPharma Dive
Thu, 07/25/19 - 12:00 pm
Editas Medicine
Allergan
clinical trials
CRISPR
EDIT-101
Allergan and Editas exercise CRISPR option
Biopharma Dive
Tue, 08/7/18 - 11:49 am
Allergan
Editas Medicine
CRISPR
EDIT-101
gene editing